Philip Gotwals Sells Shares of OmniAb, Inc.

On June 17, 2026, Philip Gotwals sold 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). The transaction didn't specify a value or price, and it wasn't part of a planned trading program.

What Changed in Philip Gotwals' OmniAb, Inc. Position

Philip Gotwals reduced his holdings in OmniAb, Inc. by 20,000 shares. This insider transaction didn't disclose the exact financial impact, as it reported a zero transaction value.

Other Institutional Activity in OmniAb, Inc.

Several major institutional investors have also made moves in OmniAb, Inc. recently. BlackRock, Inc. increased its holdings by 41,900 shares, bringing its total to 8,106,881 shares valued at approximately $12.73 million. Geode Capital Management, LLC added 202,887 shares, ending with 2,925,579 shares worth around $4.59 million. Meanwhile, Cadian Capital Management, LP trimmed its position by 277,825 shares, holding 4,157,129 shares valued at about $6.53 million.

OmniAb, Inc. Stock Snapshot

Shares of OmniAb, Inc. (NasdaqGM: OABI) traded near $2.34. The company has a market cap of approximately $339.2 million. Its forward P/E ratio isn't meaningful due to the company's lack of profitability, with a negative EPS of $-0.46. The stock's 52-week range is between $1.3 and $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80. OmniAb, Inc. has a current ratio of 4.80, a quick ratio of 4.55, and a debt-to-equity ratio of 7.49.

Recent Earnings

OmniAb, Inc. reported revenue of $28.94 million, with a modest growth rate of 2.47%. The company's net margin is negative at -187.59%, and its return on equity is -20.25%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at OmniAb, Inc.

On the same day, Jennifer Cochran bought 40,000 shares and sold 20,000 shares, while Carolyn Bertozzi bought 60,000 shares and sold 20,000 shares. John Higgins also bought 20,000 shares. These transactions were not part of any planned trading programs.

Analysts Set New Price Targets

Analysts have been active in setting price targets for OmniAb, Inc. RBC Capital maintained its 'buy' rating with a $3.00 target on August 7, 2025. Benchmark reiterated a 'buy' rating with a $6.00 target on May 12, 2025. HC Wainwright & Co. reiterated a 'buy' rating with an $11.00 target on March 19, 2025. The consensus target price among analysts is $7.33 based on six opinions.

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company based in Emeryville, California. It licenses discovery research technology to pharmaceutical and biotech companies, enabling the discovery of new therapeutics. The company uses its OmniAb platform to develop optimized antibodies for human therapeutics. It operates globally, including in the United States, Europe, Japan, China, and Canada, and employs 89 people under the leadership of CEO Matthew W. Foehr.

Bottom Line

Philip Gotwals' recent sale of OmniAb shares is part of a broader pattern of insider trading activity at the company. While the stock has shown some volatility, institutional investors like BlackRock and Geode Capital Management have made notable adjustments to their positions. Investors often watch these insider and institutional moves for insights, though it's important to remember that such data is just one piece of the investment puzzle.